The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours

The aim of this study was to use the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay to determine the response of 17 endometrial and 27 cervical tumours to cytotoxic drugs. Tumour samples were taken at surgery and cultured using the...

Full description

Saved in:
Bibliographic Details
Published in:Cancer detection and prevention 2003, Vol.27 (1), p.47-54
Main Authors: O’Toole, Sharon A., Sheppard, Brian L., McGuinness, Eamon P.J., Gleeson, Noreen C., Yoneda, Misaho, Bonnar, John
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Cancer
Cancer therapies
Cell cycle
Cell growth
Cell Survival - drug effects
Cells, Cultured
Cervix
Chemotherapy
Cisplatin - pharmacology
Clinical correlation
Cytotoxicity
Cytotoxicity assay
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor - methods
Drug Therapy, Combination
Endometrial cancer
Endometrial Neoplasms - drug therapy
Endometrium
Epidemiology
Female
Fluorouracil - pharmacology
Genital Neoplasms, Female - drug therapy
Humans
Mortality
Neoplasm Staging
Ovarian cancer
Ovary
Paclitaxel - pharmacology
Retrospective Studies
Tetrazolium Salts
Topotecan - pharmacology
Toxicity Tests - methods
Treatment Outcome
Tumors
Uterine Cervical Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to use the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay to determine the response of 17 endometrial and 27 cervical tumours to cytotoxic drugs. Tumour samples were taken at surgery and cultured using the explant technique. Cells were incubated with chemotherapy drugs. The MTS cytotoxicity assay was carried out to ascertain the response to the drugs and correlated retrospectively to the clinical outcome. Tumours of similar stage and grade displayed heterogeneity in their responses to the drugs. A total of 88 of 90 tumours (97.8%), including data from an earlier study of 44 ovarian tumour samples yielded chemosensitivity data. A total of 45 specimens were evaluable for in vitro–in vivo correlations. In vitro sensitivity was associated with clinical response in 26 of 30 patients and in vitro resistance with progressive disease or death in 14 of 15 patients. A randomised prospective trial should be carried out to validate chemosensitivity/resistance testing.
ISSN:0361-090X
1877-7821
1873-443X
1877-783X
DOI:10.1016/S0361-090X(02)00171-X